Navigation Links
Researchers identify a histone demethylase associated with non-small cell lung cancer
Date:11/8/2013

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond. Recent studies of other cancers indicate that the global changes in DNA methylation patterns may drive tumor formation.

In this issue of the Journal of Clinical Investigation, MinGyu Lee and colleagues at MD Anderson Cancer Center evaluated histone methylation modifications in NSCLS cell lines and determined that the histone demethylase KDM2A was upregulated in NSCLC cell lines. Furthermore, induced KDM2A expression increased cell proliferation and invasiveness through activation of the ERK1/2 signaling pathway. Evaluation of tumors from NSCLS patients uncovered a correlation between increased levels of KDM2A and poor prognosis.

This study suggests that therapies targeting KDM2A may benefit a subset of NSCLS patients.


'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers at Pace University Explore the Lived Experiences of Families Members That Have the Possible Risk of Genetic Mutations That Cause Sudden Cardiac Death
2. UT Southwestern researchers discover a new driver of breast cancer
3. Sanders-Brown researchers produce new research on little-understood brain disease
4. UCSF researchers offer solutions to looming health-care provider shortage
5. Hot-air balloon rides -- researchers advise, proceed with caution
6. Researchers gain new insights into brain neuronal networks
7. Researchers warn of the myths of global medical tourism
8. Canadian researchers discover how to measure quality of life for rare blood condition
9. Kessler researchers find aerobic exercise benefits memory in persons with multiple sclerosis
10. Voices Against Brain Cancer Commends Researchers for the Identification of an Important Protein that May Give Insight to More Effective Glioblastoma Treatments
11. Increasing rate of knee replacements linked to obesity among young, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical ... staff with the addition of industry sales leader, Thomas (Tom) Slott, as Senior ... national distribution and sales network, direct the efforts of the surgical sales teams, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: